Moderna, Inc. Deferred Income Tax Liabilities, Net
Moderna, Inc. (MRNA) had Deferred Income Tax Liabilities, Net of $255.00 million as of 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:DeferredIncomeTaxLiabilitiesNet · last filed 2026-07-31
- 2026-06-30: Deferred Income Tax Liabilities, Net $255.00M.
- 2026-03-31: Deferred Income Tax Liabilities, Net $253.00M.
- 2025-12-31: Deferred Income Tax Liabilities, Net $249.00M.
- 2025-09-30: Deferred Income Tax Liabilities, Net $239.00M.
| Period end | Deferred Income Tax Liabilities, Net |
|---|---|
| 2026-06-30 | $255.00M 10-Q · filed 2026-07-31 |
| 2026-03-31 | $253.00M 10-Q · filed 2026-05-01 |
| 2025-12-31 | $249.00M 10-Q · filed 2026-07-31 |
| 2025-09-30 | $239.00M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $237.00M 10-Q · filed 2025-08-01 |
| 2025-03-31 | $234.00M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $231.00M 10-K · filed 2026-02-20 |
| 2024-09-30 | $241.00M 10-Q · filed 2024-11-07 |
| 2023-12-31 | $235.00M 10-K · filed 2025-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |